11th Jun 2015 07:50
LONDON (Alliance News) - Vernalis PLC said Thursday that twelve months of stability testing of its cold-cough product CCP-07 has begun, the second programme in its pipeline from its exclusive licensing agreement with Tris Pharma Inc.
Tris expects to submit the product to the US Food and Drug Administration in 2016. The first product from the pipeline, Tuzistra XR, was approved by the FDA at the end of April.
Under their agreement Tris is developing up to-six cough cold treatments. The financial details of the deal have not been disclosed.
"We are extremely pleased with the continued progression of CCP-07 and look forward to further positive news flow from our cough cold pipeline," said Chief Executive Officer Ian Garland in a statement.
Shares in Vernalis are trading up 2.5% at 74.57 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC